April 25th 2025
An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Abbreviated MRI and Early-Stage Hepatocellular Carcinoma: What a New Multicenter Study Reveals
January 25th 2023In a multicenter study involving nearly 300 patients, researchers found that abbreviated magnetic resonance imaging (MRI) had a sensitivity rate of 88.2 percent and a specificity rate of 89.1 percent for detecting early-stage hepatocellular carcinoma (HCC).
Meta-Analysis Reaffirms Benefits of O-RADS MRI for Diagnosing Indeterminate Adnexal Lesions
December 16th 2022In addition to summary sensitivity and specificity of 92 percent and 91 percent respectively for characterization of indeterminate adnexal lesions, the meta-analysis on pelvic magnetic resonance imaging (MRI) revealed higher summary malignancy rates for O-RADS MRI 4 and 5 lesions than predicted.
Could an Emerging AI Platform Supplant Traditional MRI for Assessing Prostate Cancer?
December 7th 2022The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.
What BI-RADS Changes Are on the Way for Breast MRI Reporting?
December 2nd 2022In a recent lecture at the Radiological Society of North America (RSNA) conference, Wendy DeMartini, MD, discussed a variety of preliminary proposed changes to the Breast Imaging Reporting and Data System (BI-RADS) for breast magnetic resonance imaging (MRI) examinations.
Can MRI-Based Prostate Cancer Screening be a Viable Alternative to PSA Testing?
December 1st 2022In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.
Enhancing MRI Efficiency and Quality: Can the New SIGNA Experience Have an Impact?
November 29th 2022Recently launched at the Radiological Society of North America (RSNA) conference, the SIGNA Experience reportedly features synergistic technologies and artificial intelligence (AI) advances that help improve the efficiency and quality of magnetic resonance imaging.
Current Insights on AI, Breast Cancer Screening and the FDA
November 8th 2022In a recently published article, researchers from Yale University discuss the pros and cons of current FDA regulations as they apply to the clearance and use of adjunctive artificial intelligence (AI) software with conventional breast cancer screening modalities such as mammography.
Radiotherapy for Prostate Cancer: Study Says MRI Guidance Significantly Reduces GU and GI Toxicities
October 28th 2022For patients undergoing stereotactic body radiotherapy (SBRT) for prostate cancer, the acute genitourinary (GU) toxicity rate associated with the procedure was 19 percent lower with magnetic resonance imaging (MRI) guidance in comparison to computed tomography (CT) guidance, according to new research presented recently at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Transvaginal Ultrasound or MRI: Which is More Effective in Evaluating Endometrial Cancer?
October 26th 2022In a new study looking at pre-operative assessment of low-grade endometrial cancer, researchers found that while magnetic resonance imaging (MRI) had 20 percent higher specificity than transvaginal ultrasound for deep myometrial invasion, there was no difference in sensitivity.
Study Suggests Shorter Duration of Radiation Therapy is Effective for High-Risk Prostate Cancer
October 24th 2022Five weeks of radiation therapy is just as effective as eight weeks of radiation treatment for men with high-risk prostate cancer, according to new research presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Philips Gets FDA Nod for MRI Head and Neck Radiotherapy Application
October 20th 2022For physicians performing radiotherapy treatment of soft tissue tumors in the head and neck, the MRCAT Head and Neck offers an artificial intelligence (AI) application that allows the use of magnetic resonance imaging (MRI) as the primary or sole imaging for procedure planning.
Recognizing the Role of Enterprise Imaging in Handling and Protecting Sensitive Patient Information
October 19th 2022While facilitating interdisciplinary colloaboration is a central objective with enterprise imaging platforms, this author says implementation of these platforms must ensure optimal patient privacy in sensitive cases involving abuse, assault and domestic violence.
Could Brain MRI Screening be Beneficial for Patients with Inflammatory Breast Cancer?
October 11th 2022While current consensus guidelines do not recommend the use of brain MRI screening in patients with breast cancer, a new study shows significantly elevated risks for the development of central nervous system metastasis in patients with inflammatory breast cancer.
Adjunctive AI Software for Brain MRI Gets FDA Clearance for Assessing High-Grade Gliomas
October 10th 2022Incorporating artificial intelligence (AI)-based technology, Neosoma HGG reportedly demonstrated a 95.5 percent accuracy rate in measuring brain tumor volume on brain magnetic resonance imaging (MRI) scans at various points during the treatment of patients with high-grade gliomas.